Another study showed other mutations in CRBN in MM patient who was initially responsive to thalidomide and lenalidomide treatment, who acquired resistance to lenalidomide over the disease course, and who was finally unresponsive to pomalidomide treatment at the time of tumor sampling. This evidence concerns the gene CRBN and neoplasm.